Sysmex (6869) AI Stock Analysis

• Market Cap: $1.54T
• Dividend Yield: 1.21%
• Average Volume (3M): 1.51M
• Price to Earnings (P/E): 28.8
• Beta (1Y): 0.72
• Revenue Growth: 10.21%
• EPS Growth: 8.55%
• Country: JP
• Employees: 10,042
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 17.72
• Shares Outstanding: 629,480,100
• 10 Day Avg. Volume: 1,205,000
• 30 Day Avg. Volume: 1,513,753
• PEG Ratio: -4.25
• Price to Book (P/B): 3.43
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 26.98
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $3,224.61
• Price Target Upside: 30.02% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 78 Outperform
• Price Target: ¥2,824.00 ▲(13.87%Upside)

Sysmex's strong financial performance is the primary driver of its stock score, reflecting robust growth and stability. However, technical indicators and valuation metrics suggest moderate caution, given the current market conditions and stock valuation.

Sysmex Business Overview & Revenue Model

Company Description

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. The company offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. It also provides urine formed sediment analysis systems; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, the company offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; cancer genome profiling systems; and cytogenic testing and lab assay services. It is also involved in the development and sale of software for diagnostic information systems; provision of facility management, office, and welfare services; development, manufacture, and sale of nucleic acid analogs; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. Sysmex Corporation has a strategic alliance with QIAGEN N.V. for the development and commercialization of cancer companion diagnostics using Plasma-Safe-SeqS technology. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.

How the Company Makes Money

Sysmex generates revenue primarily through the sale of its diagnostic testing systems and related reagents. The company’s business model is built on the continuous supply of consumables such as reagents and test kits, which are used alongside their diagnostic equipment, ensuring a steady stream of recurring revenue. Additionally, Sysmex offers maintenance services and software solutions, which further contribute to its earnings. The company benefits from strategic partnerships with healthcare providers and institutions, leveraging these relationships to expand its market presence and secure long-term contracts. Sysmex’s global distribution network and strong focus on research and development enable it to introduce new and advanced diagnostic solutions, maintaining its competitive edge and driving revenue growth.

Sysmex Financial Statement Overview

Summary

Sysmex exhibits strong financial performance across all key areas. The company has demonstrated robust revenue and profit growth, efficient operational management, and strong cash generation. The balance sheet reflects a stable financial position with low leverage and high equity. These factors collectively indicate a well-managed company with a sustainable financial trajectory in the medical instruments and supplies industry.

Income Statement

Sysmex has demonstrated strong revenue growth over the past five years, with a notable increase of 10.2% from the previous year. The company maintains a healthy gross profit margin of approximately 53.5% and a consistent net profit margin of 10.5%. The EBIT margin stands at 17.6%, reflecting efficient operational management. EBITDA margin is solid at 24.3%, indicating robust operational cash generation. Overall, the income statement reflects strong profitability and growth trends.

Balance Sheet

Sysmex's balance sheet is characterized by a strong equity position, with an equity ratio of 69.7%, highlighting financial stability. The debt-to-equity ratio is manageable at 0.14, indicating low leverage risk. Return on equity (ROE) is a solid 11.6%, demonstrating effective use of shareholder funds. Overall, the balance sheet reflects a stable financial structure with low leverage and strong equity.

Cash Flow

Cash flow analysis reveals a remarkable 330.4% growth in free cash flow, indicative of significant cash generation improvements. The operating cash flow to net income ratio is 1.64, and the free cash flow to net income ratio is 1.10, reflecting efficient conversion of income to cash. Overall, the cash flow statement shows strong liquidity and cash management, supporting the company's financial health.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	508.64B	461.51B	410.50B	363.78B	305.07B
Gross Profit	271.98B	242.50B	216.08B	190.59B	154.30B
EBITDA	123.85B	115.67B	104.95B	96.12B	75.53B
Net Income	53.67B	49.64B	45.78B	44.09B	31.90B
Balance Sheet
Total Assets	665.27B	618.92B	531.07B	483.71B	427.48B
Cash, Cash Equivalents and Short-Term Investments	89.57B	76.61B	70.33B	75.25B	67.57B
Total Debt	64.73B	55.34B	22.59B	22.28B	21.96B
Total Liabilities	200.73B	186.02B	142.72B	134.65B	118.81B
Stockholders Equity	463.78B	432.05B	387.67B	348.30B	307.90B
Cash Flow
Free Cash Flow	59.02B	13.71B	26.33B	26.70B	33.02B
Operating Cash Flow	88.25B	63.91B	68.83B	58.74B	58.81B
Investing Cash Flow	-52.49B	-54.97B	-51.75B	-35.05B	-31.13B
Financing Cash Flow	-24.32B	-9.01B	-24.23B	-20.54B	-20.25B

Sysmex Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2480.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6869, the sentiment is Negative. The current price of 2480 is above the 20-day moving average (MA) of 2476.47, above the 50-day MA of 2456.87, and below the 200-day MA of 2742.61, indicating a neutral trend. The MACD of 5.61 indicates Positive momentum. The RSI at 49.72 is Neutral, neither overbought nor oversold. The STOCH value of 55.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6869.

Sysmex Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6869	78 Outperform	$1.54T	28.78	11.84%	1.21%	10.21%	8.55%
Sector *	51 Neutral	$7.35B	0.50	-65.61%	2.47%	15.28%	1.44%
TRUMF	―	$25.08B	34.54	8.56%	0.99%	―	―
AHICF	―	$4.26B	61.28	7.09%	1.00%	―	―
HOCPF	―	$43.53B	33.14	20.56%	0.91%	―	―
5FA	―	€1.32B	41.51	2.07%	2.45%	―	―
OCPNF	―	$13.52B	17.91	15.47%	1.10%	―	―

Sysmex Corporate Events

Sysmex Introduces Performance-Linked Stock Compensation Plan

Sysmex Corporation has announced the introduction of a performance-linked stock compensation plan for its Managing Board members and Executive Officers, excluding certain directors and nonresidents of Japan. This plan aims to align the interests of the board members with shareholders by linking their compensation to the company’s performance and stock value, thereby encouraging them to contribute to the company’s long-term growth. The plan will replace the current officer shareholding association system and stock options, pending approval at the upcoming Shareholders’ Meeting. The new compensation structure will include fixed compensation, performance-linked compensation, and stock-based compensation, with oversight from a Compensation Committee to ensure independence and accountability.

The most recent analyst rating on (JP:6869) stock is a Buy with a Yen3500.00 price target. To see the full list of analyst forecasts on Sysmex stock, see the JP:6869 Stock Forecast page.

Sysmex Adjusts Deferred Tax Assets in Non-Consolidated Results

Sysmex Corporation has announced a reversal of deferred tax assets in its non-consolidated financial results for the fiscal year ending March 31, 2025. This adjustment, amounting to ¥10,983 million, reflects a reassessment of the recoverability of these assets considering the future business environment. Importantly, this reversal does not impact the company’s consolidated financial results, which adhere to International Financial Reporting Standards (IFRS), thus maintaining stability in its overall financial positioning.

The most recent analyst rating on (JP:6869) stock is a Buy with a Yen3500.00 price target. To see the full list of analyst forecasts on Sysmex stock, see the JP:6869 Stock Forecast page.

Sysmex Reports Minor Forecast Deviations and Declares Year-End Dividend

Sysmex Corporation announced a slight deviation from its financial forecast for the fiscal year ending March 31, 2025, with actual results showing a minor shortfall in net sales and profits due to weaker performance in certain regions despite strong sales in the Americas and Japan. The company also declared a year-end dividend of ¥17 per share, resulting in a total annual dividend of ¥32 per share, reflecting a consolidated payout ratio of 37.4%, aligning with its policy of stable shareholder returns.

The most recent analyst rating on (JP:6869) stock is a Buy with a Yen3500.00 price target. To see the full list of analyst forecasts on Sysmex stock, see the JP:6869 Stock Forecast page.

Sysmex Reports Strong Financial Growth and Announces Stock Split

Sysmex Corporation reported a strong financial performance for the fiscal year ending March 31, 2025, with a notable increase in net sales and operating profit compared to the previous year. The company also announced a three-for-one stock split and adjusted its dividend payouts accordingly. These financial results reflect Sysmex’s robust market positioning and strategic growth initiatives, which are likely to have positive implications for stakeholders and reinforce its competitive stance in the healthcare diagnostics sector.

The most recent analyst rating on (JP:6869) stock is a Buy with a Yen3500.00 price target. To see the full list of analyst forecasts on Sysmex stock, see the JP:6869 Stock Forecast page.